PhaseBio Pharmaceuticals

NasdaqGM:PHAS Stock Report

Mkt Cap: US$39.7m

PhaseBio Pharmaceuticals Management

How experienced are the management team and are they aligned to shareholders interests?

2.9yrs

Average management tenure


CEO

Jonathan Mow (57 yo)

7.5yrs

Tenure

US$1,529,108

Compensation

Mr. Jonathan P. Mow, MBA has been Chief Executive Officer of PhaseBio Pharmaceuticals, Inc. since March 2015 and serves as its President. Mr. Mow served as Chief Business Officer of PhaseBio Pharmaceutical...


CEO Compensation Analysis

Compensation vs Market: Jonathan's total compensation ($USD1.53M) is above average for companies of similar size in the US market ($USD776.35K).

Compensation vs Earnings: Jonathan's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: PHAS's management team is considered experienced (2.9 years average tenure).


Board Members

Experienced Board: PHAS's board of directors are considered experienced (4 years average tenure).